Project Grant F32CA306190
Award Date 1/18/26
Completion Date Not listed
Dollars Obligated $88K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $147,486 to Yale University to elucidate the mechanisms underlying the progression of non-small cell lung cancer (NSCLC) to leptomeningeal disease (LMD). The primary objectives are to identify the pathophysiological mechanisms driving the progression to LMD, particularly in cases of EGFR-mutant NSCLC that become resistant to tyrosine kinase inhibitor (TKI) treatment. The research...
- This Cooperative Agreement award for $639,882, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at the University of North Carolina at Chapel Hill to elucidate the molecular mechanisms of metastasis organ tropism in breast cancer. The key objectives are to: Identify molecular determinants of lung and liver organ-specific metastasis using a comprehensive dataset of human primary tumors and metastases, as well as genetically...
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- The University of South Alabama was awarded a $369,868 Project Grant from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) on July 7, 2025. The grant supports research to investigate the functional role of the intercellular transfer of mitochondria between nerves and cancer cells, particularly in the context of triple-negative breast cancer metastasis. The key objectives of the 5-year project are to: 1) Determine the contribution of nerve-to-cancer mitochondrial transfer in...
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
- This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct research on uncovering the cellular and molecular drivers behind the aggressive metastatic potential of small cell lung cancer (SCLC). The project aims to leverage innovative human pluripotent stem cell-derived models of SCLC to gain deeper insights into this complex issue. By examining cell behavior in both primary tumors and...
- This $147,486 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to characterize and define the role of glycosylated RNAs (glycoRNAs) in acute myeloid leukemia (AML) at Yale University. The research aims to 1) characterize glycoRNA expression and sequences in different AML subtypes compared to normal myeloid progenitors, 2) define the role of SIDT proteins in AML glycoRNA expression, and 3) determine the functions...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...